LUM001

Phase 2Small molecule

MMirum Pharmaceuticals, Inc.

LUM001 is one of 69 small molecule programs targeting Cholestatic liver disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cholestatic Liver DiseaseActive, not recruiting

Primary Biliary CirrhosisActive, not recruiting

Sclerosing CholangitisActive, not recruiting

Cholestatic Liver DiseasePhase 2

Active, not recruiting

Primary Biliary CirrhosisPhase 2

Active, not recruiting

Sclerosing CholangitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

52 competitors in Sclerosing Cholangitis

#DrugCompanyPhaseTrials

Vancocin

HHikma Pharmaceuticals LLC

Approved

9 2

Actigall

Mitosol

Retin-a

VValeant Pharmaceuticals

Approved

—5

Amoxil

GGlobal Antibiotics Research and Development Partnership

Zocor

1 7

Azulfidine

Pfizer

Phase 2

1 8

Iqirvo

Ipsen

Phase 2

1 9

Thalomid

Bristol-Myers Squibb

Phase 2

1 10

Tricor

JJagotec

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cholestatic liver disease4 trials

Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome

Completed·MMirum Pharmaceuticals, Inc.·Phase 2·NCT01903460·20 enrolled

An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome

Completed·MMirum Pharmaceuticals, Inc.·Phase 2·NCT02117713·34 enrolled

Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis

Completed·MMirum Pharmaceuticals, Inc.·Phase 2·NCT02057718·33 enrolled

Show 1 more trial

An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS)

Completed·MMirum Pharmaceuticals, Inc.·Phase 2·NCT02047318·19 enrolled

Primary Biliary Cirrhosis2 trials

Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis

Completed·MMirum Pharmaceuticals, Inc.·Phase 2·NCT01904058·66 enrolled

An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis

Withdrawn·MMirum Pharmaceuticals, Inc.·Phase 2·NCT02321306

Sclerosing Cholangitis1 trial

Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis

Completed·MMirum Pharmaceuticals, Inc.·Phase 2·NCT02061540·27 enrolled

Safety and Efficacy1 trial

Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS)

Completed·MMirum Pharmaceuticals, Inc.·Phase 2·NCT02160782·31 enrolled

Pruritus1 trial

Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome

Completed·MMirum Pharmaceuticals, Inc.·Phase 2·NCT02057692·37 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for LUM001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LUM001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LUM001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mirum Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMirum Pharmaceuticals, Inc.

LUM001

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cholestatic liver disease4 trials

Primary Biliary Cirrhosis2 trials

Sclerosing Cholangitis1 trial

Safety and Efficacy1 trial

Pruritus1 trial

References

Drug Info

Quick Facts

Related News